KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Capital Leases (2021 - 2025)

Historic Capital Leases for Bionano Genomics (BNGO) over the last 5 years, with Q3 2025 value amounting to $3.5 million.

  • Bionano Genomics' Capital Leases fell 157.7% to $3.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.5 million, marking a year-over-year decrease of 157.7%. This contributed to the annual value of $3.5 million for FY2024, which is 128.31% down from last year.
  • Per Bionano Genomics' latest filing, its Capital Leases stood at $3.5 million for Q3 2025, which was down 157.7% from $3.5 million recorded in Q2 2025.
  • Bionano Genomics' 5-year Capital Leases high stood at $3.6 million for Q4 2021, and its period low was $3.5 million during Q3 2025.
  • For the 5-year period, Bionano Genomics' Capital Leases averaged around $3.6 million, with its median value being $3.6 million (2023).
  • Its Capital Leases has fluctuated over the past 5 years, first plummeted by 63.15% in 2022, then tumbled by 157.7% in 2025.
  • Quarter analysis of 5 years shows Bionano Genomics' Capital Leases stood at $3.6 million in 2021, then dropped by 0.63% to $3.6 million in 2022, then fell by 0.94% to $3.6 million in 2023, then dropped by 1.28% to $3.5 million in 2024, then fell by 1.24% to $3.5 million in 2025.
  • Its Capital Leases was $3.5 million in Q3 2025, compared to $3.5 million in Q2 2025 and $3.5 million in Q1 2025.